Rallybio (NASDAQ:RLYB) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Rallybio (NASDAQ:RLYB) from a hold rating to a sell rating in a research note published on Sunday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Rallybio presently has an average rating of “Reduce” and a consensus price target of $5.00.

Rallybio Stock Down 7.7%

Shares of Rallybio stock opened at $0.51 on Friday. The company has a market cap of $21.35 million, a PE ratio of -0.54 and a beta of -1.10. Rallybio has a 52 week low of $0.22 and a 52 week high of $1.24. The business has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.43.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The firm had revenue of $0.21 million during the quarter. Rallybio had a negative return on equity of 71.66% and a negative net margin of 5,473.33%. As a group, research analysts anticipate that Rallybio will post -1.34 EPS for the current year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.